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From March 7980 to July 7987, 7000 patients with various end-stage liver diseases 
"received orthotopic liver transplants. Of the 7000 patients, three hundred two had 
definite histories of bleeding from esophageal varices before transplantation. There were 
287 patients with nonalcoholic liver diseases and 15 patients with alcoholic cirrhosis. 
All patients had very poor liver function, which was the main indication for liver 
transplantation. One- through 5-year actuarial survival rates of the 302 patients were 
79%, 74%, 71%, 71%, and 71%, respectively. These survival rates are far better than 
those obtained with other available modes of treatment for bleeding varices when liver 
disease is advanced. Long-term sclerotherapy is the treatment of primary choice for 
bleeding varices. Patients in whom sclerotherapy fails should be considered for liver / 
transplantation unless clear contraindications exist. (SURGERY 7988;104:697-705.) V 
From the Departments of Surgery and Medicine, University Health Center of Pittsburgh, 
University of Pittsburgh, and the Veterans Administration Medical Center, Pittsburgh, Pa. 
MASSIVE HEMORRHAGE FROM esophageal varices is the 
most devastating complication of portal hypertension in 
advanced cirrhosis. Several types of portasystemic 
shunt operations, portoazygous devascularization (non-
shunt operation), and endoscopic sclerotherapy have 
established their own roles, but they all have certain 
major limitations, particularly when the liver disease is 
far advanced. Portasystemic shunt is the most effective 
way to control bleeding from esophageal varices, but it 
is plagued by a high incidence of hepatic encephalopa-
thy and progressive hepatic failure after the shunt. 
Although they do not alter hepatic circulation, non-
shunt operations and sclerotherapy have high inci-
dences of recurrent bleeding. 
Liver transplantation has long been, at least in 
theory, the most logical treatment for bleeding esopha-
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geal varices in patients with far-advanced liver disease. 
As the results of liver transplantation have significantly 
improved in recent years, the role of this procedure in 
the treatment of bleeding esophageal varices should be 
closely examined. 
PATIENTS AND METHODS 
From March 1980 to July 1987, 1000 patients with 
various liver diseases received orthotopic liver trans-
plants at the University of Colorado Health Sciences 
Center (in 1980), the University Health Center of 
Pittsburgh (since 1981), and the Pittsburgh-affiliated 
Baylor University Medical Center at Dallas (since 
1985). Basic immunosuppressive therapy consisted of 
cyclosporine and corticosteroids, and azathioprine and 
monoclonal anti-T-Iymphocyte antibody (OKT-3) 
were added to the basic immunosuppression when 
needed. Of the 1000 consecutive liver recipients, 666 
were adults of 18 years or older and 334 were children 
younger than 18 years. The liver diseases of adult 
recipients as well as the numbers of patients with each 
disease are listed in Table I; the same data for pediatric 
recipients are listed in Table II. The three most 
common liver diseases among adult recipients were (1) 
postnecrotic cirrhosis (including chronic active hepati-
tis and cryptogenic cirrhosis), (2) primary biliary 
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Table I. Liver diseases of adult recipients 
No. of 
Disease patients 
I. Cirrhosis (postnecrotic, cryptogenic, 279 
alcoholic) 
Postnecrotic and cryptogenic 237 
(HBsAg positive 36 
Alcoholic 41 
2. Primary biliary cirrhosis 166 
3. Primary sclerosing cholangitis 82 
Associated with bile duct cancer 88 
4. Liver-based inborn metabolic errors 35 
(alpha-t-antitrypsin deficiency, 
Wilson's, etc) 
5. Primary hepatic malignancy 33 
6. Fulminant hepatic failure 25 
7. Secondary biliary cirrhosis 13 
8. Budd-Chiari syndrome 13 
9. Secondary hepatic malignancy 7 
10. Bile duct cancer without sclerosing 2 
cholangitis 
t1. Others 
.J.l 
Total 666 
cirrhosis, and (3) primary sclerosing cholangitis. The 
most common diagnoses in pediatric recipients were (1) 
biliary atresia (including extrahepatic and intrahepatic 
type, biliary hypoplasia, and Alagille's syndrome), (2) 
liver-based inborn metabolic errors (alpha-I-antitryp-
sin deficiency disease, Wilson's disease, tyrosinemia, 
and others), and (3) postnecrotic cirrhosis. 
A total of 302 liver recipients had definite histories of 
hemorrhage from esophageal varices before liver trans-
plantation; 217 were adults and 85 were children. The 
types of liver disease in these adult and pediatric 
variceal bleeders and the number of patients affected 
are listed in Tables III and IV. The liver function and 
the general condition of these 302 patients were all very 
poor and were classified in Child's class C category. 
Furthermore, 22 patients had undergone nonselective 
shunt, 15 patients had undergone selective shunt, and 5 
patients had undergone nonshunt operations for treat-
ment of bleeding esophageal varices before liver trans-
plantation. Two hundred nineteen patients had under-
gone endoscopic sclerotherapy for esophageal varices. 
The survival data were analyzed as of Feb. 1, 1988, 
by the method of Kaplan-Meier. The follow-up period 
ranged from 6 months to 6 years 11 months, with a 
median follow-up of 2 years 3 months. None of the 
patients was lost from the follow-up. The statistical 
comparisons were made by the methods of Breslow and 
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Table n. Liver diseases of pediatric recipients 
No. of 
Disease patients 
1. Biliary atresia 179 
2. Liver-based inborn metabolic errors 63 
(alpha-t-antitrypsin deficiency, 
Wilson's, etc.). 
3. Cirrhosis (postnecrotic, cryptogenic) 40 
4. Familial cholestatic syndrome 15 
5. Fulminant hepatic failure 12 
6. Secondary biliary cirrhosis 8 
7. Congenital hepatic fibrosis 6 
8. Primary hepatic malignancy 3 
9. Budd-Chiari syndrome 2 
10. Neonatal hepatitis 2 
1l. Others 
--1 
Total 334 
of Mantel-Cox. The difference was considered as 
significant when p value was less than 0.05 . 
RESULTS 
The overall survival rates of the 1000 consecutive 
patients after liver transplantation were 72% at 1 year, 
67% at 2 years, 65% at 3 years, 64% at 4 years, and 
63% at 5 years with cyclosporine-steroid therapy. 
These survivals were three times higher than those 
obtained with azathioprine-steroid therapy before 1980 
(Fig. 1). The survival rates of 666 adult recipients were 
nearly identical to those of 334 pediatric recipients. 
The survival rates of 302 patients who had bled from 
esophageal varices before transplantation (esophageal 
bleeders) were 79% at 1 year, 74% at 2 years, and 71 % 
at 3, 4, and 5 years after transplantation. Survival of 
698 patients who had no history of variceal bleeding 
(variceal non bleeders) was 69% at 1 year, 64% at 2 
years, 62% at 3 years, 60% at 4 years, and 59% at 5 
years. The survival rates of variceal bleeders were 
significantly higher than those of non bleeders 
(p < 0.01), as shown in Fig. 2. The survival rates of 
217 adult esophageal bleeders were 78% at 1 year, 73% 
at 2 years, and 68% at 3, 4, and 5 years after 
transplantation, and those of 85 pediatric esophageal 
bleeders were 80% at 1 year and 77% at 2, 3, 4, and 5 
years. There was no statistically significant difference 
in survival rates between adult and pediatric esophage-
al bleeders. 
The survival rates after liver transplantation were 
compared among the esophageal bleeders with the 
three most common adult liver diseases (Fig. 3) and 
also among those with the three most common pediatric 
Volume 104 
Number 4 
100 
...J , 
~ 80 ~ 
I I I I I I 
-
-
eYA (n = 1.000) 5: ~-II-KKKKKI ~ 60 r \ '---"'L-_ ....... ____ -
I- h. fE 40 r ''\:).._ 
() ... "'()., OC ...... "'()., ...... 
AZA (n = 170) 
w 20 "'0... ... Cl. r "'-0-_ --0-
I 
1 
I I I 
2 3 4 
YEAR 
I I 
5 
Fig. 1. Survival rates after liver transplantation have 
improved significantly since the introduction of cyclosporine 
in 1980. CyA, cyclosporine group, 1,000 patients; AZA, 
azathioprine group, 170 patients. 
Table m .. Liver diseases of adult recipients 
who had a definite history of bleeding from 
esophageal varices 
Disease 
1. Posmecrotic and cryptogenic 
cirrhosis 
2. Primary biliary cirrhosis 
3. Primary sclerosing cholangitis 
4. Liver-based inborn metabolic errors 
(alpha-I-antitrypsin deficiency, 
Wilson's, etc.) 
5. Alcoholic cirrhosis 
6. Secondary biliary cirrhosis 
7. Budd-Chiari syndrome 
8. Biliary atresia 
Total 
No. of 
patients 
85 
63 
31 
16 
15 
4 
2 
1 
217 
liver diseases (Fig. 4). There was no statistically 
significant difference in survival rates among the liver 
diseases in either the adult or the pediatric esoph-
ageal bleeders. The survival rates of 15 variceal 
bleeders with alcoholic cirrhosis were 93% at 1 year 
and 76% at 2 years after transplantation; these rates 
were similar to those of patients with nonalcoholic liver 
disease. 
There were 42 patients who had had some kind of 
operation for bleeding esophageal varices (22 nonselec-
tive shunts, 15 selective shunts, and 5 nonshunt opera-
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Fig. 2. Survival rates of 302 patients who had bled from 
esophageal varices before transplantation (esophageal bleed-
ers) were better than those of 698 patients who had not bled 
(esophageal nonbleeders). The difference was statistically 
significant I.p = 0.002). 
Table IV. Liver disease of pediatric recipients 
who had a definite history of bleeding from 
esophageal varices 
No. of 
Disease patients 
1. Biliary atresia 37 
2. Liver-based inborn metabolic errors 19 
(alpha-I-antitrypsin deficiency, 
Wilson's etc.) 
3. Postnecrotic and cryptogenic 15 
cirrhosis 
4. Congenital hepatic fibrosis 5 
5. Familial cholestatic syndrome 4 
6. Secondary biliary cirrhosis 4 
7. Primary sclerosing cholangitis 
...l 
Total 85 
tions). The survival rates of these 42 patients were 71 % 
at 1 and 2 years and 65% at 3, 4, and 5 years after 
transplantation. Survival rates of the 260 patients who 
had not had an operation for bleeding varices were 80% 
at 1 year, 75% at 2 years, and 73% at 3, 4, and 5 years 
after transplantation (Fig. 5). Seven (17%) of 42 
patients of the former group died within a month after 
transplantation, in contrast with 21 (8%) of the 260 
patients of the latter group. However, the differences in 
short- and long-term survival rates of the two groups 
have not reached statistical significance. 
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Fig. 3. Survival rates of esophageal bleeders were similar 
among the three most common adult liver diseases. GIR, 
posmecrotic or cryptogenic cirrhosis; PBG, primary biliary 
cirrhosis; PSG, primary sclerosing cholangitis. 
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Fig. 4. Survival rates of esophageal bleeders were similar 
among the three most common pediatric liver diseases. BA, 
biliary atresia; MET AB, li\·er-based inborn metabolic errors; 
GIR, postnecrotic or cryptogenic cirrhosis. 
DISCUSSION 
For more than four decades, portal-systemic shunts 
were readily accepted as the most effective treatment of 
bleeding from esophageal varices. Enthusiasm, howev-
er, started to wane more than two decades ago, when it 
became apparent that the price of preventing hemor-
rhage from esophageal varices by portal-systemic 
shunts was dehumanizing encephalopathy and pro-
gressive hepatic dysfunction. 
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Fig. 5. Survival rates of 42 patients who had had some kind 
of operation for bleeding varices before liver transplantation 
were lower than those of 260 patients who had not had any 
such operation before transplantation. The difference, how-
ever, was not statistically significant. 
Three controlled studies of prophylactic portal-
systemic shunts concluded more than 15 years ago that, 
in spite of excellent protection from variceal hemor-
rhage, patients who had such shunts had poorer 
survival rates than patients who were treated with 
medical supportive measures alone, apparently because 
of increased frequency of death from hepatic failure 
among patients with shunts. 1. l Three controlled studies 
of therapeutic shunts also failed to show a statistically 
significant difference in the long-term survival rates 
between the patients with shunts and the medically 
treated patients after more than 10 years of follow-
Up .... 6 
With increasing disenchantment with portal-system-
ic shunting, considerable efforts were expended in 
developing new operations or modifying old ones that 
prevent variceal hemorrhage efficiently without signif-
icantly altering hepatic circulation. The distal spleno-
renal shunt was introduced in 1967 by Warren, Zeppa, 
and Fomon7 as a selective shunt. In the last decade, the 
effectiveness of this selective shunt has been assessed in 
five different randomized controlled studies.s.'2 All of 
these well-designed studies failed to show the survival 
superiority of selective shunt over nonselective shunt 
despite initial claims. Meanwhile, nonshunt operations 
(portal azygos disconnection) improved the old tech-
niques and achieved survival rates similar to those 
achieved with shunt operations, although the incidence 
of rebleeding was higher than with the shuntS. Il- 1I 
Since endoscopic sclerotherapy was reintroduced by 
Johnston and Rogers,'6 the long-term management of 
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Table V. Survival comparison among various treatments for bleeding esophageal varices (Child's classes 
A, B, and C) -
Treatment 
Jackson et a!. (1971) 
Nonselective shunt 
Medical 
Resnick et al. (1974), 
Nonselective shunt 
Medical 
Reynolds et al. (1981) 
Nonselective shunt 
Medical 
Conn et al. (1981) 
Selective shunt 
Nonselective shunt 
Langer et al. (1985) 
Selective shunt 
Nonselective shunt 
Millikan et at. (1985) 
Selective shunt 
Nonselective shunt 
Warren et al. (1986) 
Sclerotherapyt 
Selective shunt 
Rikkers et al. (1987) 
Sclerotherapy 
Selective shunt; 
Yamamoto et al. (1976) 
Nonshunt operation 
Sugiura et al. (1984) 
Nonshunt operation 
Spence et al. (1985) 
Nonshunt operation 
Present study (1988) 
Liver transplantation 
·Valur estimated from survival curve:. 
.'Vo. of 
patIents 
67 
77 
54 
25 
41 
37 
24 
29 
38 
40 
26 
29 
36 
35 
30 
27 
64 
256 
100 
302 
tSclerotherapy failures wert rescued by surgical therapy. 
tTwentv·three selective shunts and four nonselective shunts 
7 vr 
80* 
80 
70* 
67* 
76* 
70* 
80* 
90* 
85* 
80* 
90* 
70* 
77· 
75* 
81 
87 
73 
79 
bleeding varices by this endoscopic procedure has 
spread worldwide. 
Having failed to improve the survival rates, selective 
shunt was critically examined against long-term scler-
otherapy by two randomized trials.!7. IR In their prelim-
inary report Warren and his associatesF concluded that 
sclerotherapy gave significantly better survival than the 
selective shunt when the sclerotherapy failures were 
rescued with surgical therapy, including selective and 
nonselective shunts and nonshunt operations. Rikkers 
and his associates!8 reported that endoscopic sclerother-
apy and shunt surgery (23 selective shunts and 3 
nonselective shunts) provided similar results with 
2 yr 
73* 
66* 
58* 
52* 
72* 
60* 
70* 
67* 
76* 
85* 
77* 
72* 
84 
59 
61 
65 
75 
84 
65 
74 
Survival rates (% j 
3 yr 
62* 
43* 
50* 
40* 
64* 
44* 
63* 
70* 
65* 
70* 
82* 
45* 
60· 
60* 
70 
81 
54 
71 
4 yr 
58* 
35* 
48* 
40* 
52* 
36* 
54* 
56* 
60* 
65* 
82· 
45* 
50· 
39* 
70 
78 
51 
71 
5yr 
55* 
32* 
48* 
40* 
44 
22 
51* 
56* 
55* 
60* 
65 
78 
47 
71 
respect to survival, hepatic function, and frequency of 
encephalopathy. 
Table V compares the survival rates of 302 liver 
recipients who had a definite history of variceal hem-
orrhage with those reported in eight well-studied 
cOlitral trials of therapeutic shunt operations.·6. 1O.!2. 17. 18 
and three uncontrolled series of nonshunt opera-
tions.!3-!5 As the outcomes of shunt and nonshunt 
operations are highly influenced by the hepatic func-
tional reserve of the patients at the time of operation,19 
the results of one study cannot be simply compared 
with those of another. More than 75% of the patients in 
each report listed in Table V had good hepatic function 
-------.--- .. -----~ .. --.--.----------------
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Table VI. Survival comparison among various treatments for bleeding esophageal varices (Child's class 
C, poor liver function) 
No. of 
Treatment patients 
Turcotte et al. (1973) 
Nonselective shunt 50 
Yamamoto et al. (1976) 
Nonshunt operation 13 
Warren et al. (1982) 
Selective shunt 
Nonselective shunt 
Rikkers et al. (1 984) 
Shunt and nonshunt operationt 24 
Chandler et al. (1985) 
Shunt; 30 
Spence et al. (1985) 
Nonshunt operation 25 
Present study (1988) 
Liver transplantation 302 
·Valuc:: estimated rrom survival cur.:e, 
tFiftern nonselective ~hunlK se~·en selective- shunts. and two nonshum opc:rations. 
;Both "fr<:tiv~ and nonselective operations. 
or moderately impaired hepatic function (Child's class 
A and B), and fewer than 25% of them had advanced 
hepatic dysfunction (Child's class C). On the other 
hand, all the patients who received liver transplants 
had advanced hepatic dysfunction or far-advanced 
hepatic dysfunction. Despite this severe disadvantage of 
preoperative condition, the survival rates of liver trans-
plant recipients who had had variceal hemorrhage 
were better than or similar to those of patients who had 
had other kinds of conventional therapy (Table V). 
Because the surgical therapy for esophageal varices 
is usually withheld from the patients with advanced 
hepatic dysfunction (Child's class C), the literature 
contains few survival data for these patientsY· 15.19·22 In 
Table VI the results obtained with liver transplanta-
tion are compared with those achieved in patients with 
advanced hepatic dysfunction after conventional surgi-
cal therapy. It is obvious that the survival rates of liver 
transplant recipients are far better than those achieved 
with conventional types of surgical therapy when the 
liver disease is advanced. 
As each disease has its own natural history, the 
results of various kinds of therapy for variceal hemor-
rhage should ideally be compared among patients with 
portal hypertension of similar etiology. In the litera-
ture, however, whether the etiology of cirrhosis will 
influence long-term survival after shunt operation is a 
SurVIVal rates (%) 
1 VT 2 yr 3 yr 4 yr 5 yr 
36 32 22 20 17 
39 30 22 22 18 
60* 53· 45* 40· 35* 
50* 40* 37* 20* 15· 
45 35* 30· 20* 17* 
36 30 25 20 13 
70 53 38 38 35 
79 74 71 71 71 
matter of considerable controversy. Some investigators 
found that after shunt operations patients with nonal-
coholic cirrhosis had significantly better long-term 
survival rates than those with alcoholic cirrhosis,21. 22 
but others could not find a difference between the two 
groups.Il·24.25 Our recent review of 1000 liver trans-
plantations under cyclosporine-steroid immunosup-
pressive therapy26 has shown that the survival rates 
were similar among the three most common adult liver 
diseases (postnecrotic cirrhosis, primary biliary cirrho-
sis, and sclerosing cholangitis) and among the three 
most common pediatric liver diseases (biliary atresia, 
liver-based inborn metabolic errors, and postnecrotic 
cirrhosis). The survival rates of alcoholic cirrhosis were 
also similar to overall survival rates, although the 
numbers were small. In this study of the subgroup of 
302 patients who had bled from esophageal varices, the 
original liver diseases did not influence the survival 
rates after liver transplantation. 
The survival rates of the 42 patients who had had 
shunt or nons hunt operations for treatment of bleeding 
esophageal varices before liver transplantation were 
lower than those of patients in whom variceal hemor-
rhage was treated medically and/or with long-term 
endoscopic sclerotherapy, but the difference was not 
statistically significant. It is obvious, however, that a 
previous shunt or nonshunt operation made the trans-
-Volume 704 
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plant operation more difficult and thereby increased 
early mortality, as shown in Fig. 5. 
Recently two randomized control trials17,18 have 
shown that long-term sclerotherapy can provide the 
same (or better) survival rates as the distal splenorenal 
shunt, which is generally considered the best among 
shunt operations. Although the data are not available 
for nonshunt operations, the results can be expected to 
be similar to those of shunt operations. The survival 
rates after liver transplantation for patients with 
advanced liver disease who had bled from varices are 
quite satisfactory as presented here. There are ample 
data in the literature, as discussed, that support long-
term sclerotherapy as the treatment of first choice for 
bleeding esophageal varices. The patients in whom 
long-term sclerotherapy failed should be considered for 
liver transplantation, unless some clear contraindica-
tions for transplantation exist. We believe that shunt or 
nonshunt opertions should not be performed for treat-
ment of variceal hemorrhage, except under the most 
unusual circumstances. Liver transplantation is the 
treatment of choice for many patients with advanced 
liver disease after failure of sclerotherapy. 
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DISCUSSION 
Dr. Marvin J. Wexler (Montreal, Canada). One can't 
help but stand in awe of the tremendous experience and 
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excdlent results of the Pittsburgh group and their persever-
ance and tenacity over the years in the face of all opposition. 
The medical communitv and, indeed. the entire population of 
patients with liver disease owe a tremendous debt of grati-
tude. 
However, I think the problem being discussed-HLiver 
Transplantation in the Treatment of Bleeding Varices"-
must be put into perspective. The authors have taken a 
population of 1 000 patients who underwent liver transplan-
tation-for accepted indications of progressive end-stage liver 
failure-and retrospectively found 300 who. in their history, 
had also had hemorrhages from esophageal varices. Because 
the results of liver transplantation have been so good in this 
group, they suggest that this is the best treatment for varices, 
a logic that is faulty and unacceptable, not even a "true-true 
and unrelated" in the multiple-choice jargon. 
Let's look more closely at the 302 patients: 
1. Almost 30% were children. 
2. Fifteen percent had already had a shunt or nonshunt 
operation for varices (and, I might add, "survived"), and 72% 
had undergone successful chronic sclerotherapy. 
3. Only 15 patients had alcoholic cirrhosis; indeed, of their 
1000 patients, only 42 had alcoholic cirrhosis, believed by 
many to be the worst-risk group for transplantation. 
4. None were reported to be actively bleeding, and indeed 
none was even described as having previous unsuccessful 
variceal therapy. Having survived such treatment, they were 
therefore an excellent preselected good-risk group from the 
standpoint of their varices, despite their advanced liver 
disease. 
On the other hand. it must be pointed out that: 
1. Patients with nonalcoholic liver disease do very well 
with selective shunts, as Drs. Warren and Zeppa have 
shown. 
2. As Dr. Chung, as well as ourselves and Dr. Rikkers 
and the Emory group, has just shown, 70% to 75% of the 
patients require no treatment modality for control of their 
varices other than sclerotherapy. 
To suggest that patients in whom conventional sclerosis 
has failed will do wdl as the patients presented today is pure 
conjecture, and it demands an analysis of the reasons for (and 
the mechanism of) failure of sclerosis. Are these patients 
bleeding from esophageal necrosis or ulcer? Is there portal or 
splenic thrombosis) What are their portal hemodynamics and 
collaterals so that they fail? 
Finally, what about the conditions under which such 
therapy may be required, that is, actively bleeding or less 
than optimum conditions. both operative and nonoperative. 
not to mention cost, organ procurement, shortage, etc. 
I fear that what we may be seeing here in their enthusiasm 
may lead to the problem often seen when new treatment 
modalities succeed. which is misuse and abuse. and I would 
urge a note of caution. The ability to carry out an operation is 
not an indication to do it. . 
Dr. William Millikan (Atlanta. Ga.). I would like to 
thank Dr. Wexler for speaking first. for twO reasons. First. 
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his critical analysis of the study summarizes those things that 
needed to be said. Second. just as he reinforced the value of 
Dr. Chung's uncontrolled trial, he reiterated the need for 
controlled trials in the future, comparing other types of 
modalities for treatment of variceal bleeding with liver 
transplantation. 
This is taken from Dr. Iwatsuki's paper, and the com-
ments I am about to make represent not only my own but 
those of Drs. Warren, Henderson, Galloway, Jennings, and 
Stewart, who perform not only the shunt surgery but the liver 
transplantations at Emory. 
This statement is made and is a result of his survival 
analysis in 302 patients. We agree 100"lo that liver transplan-
tation is the treatment of choice for patients with end-stage 
liver disease, whether they have or have not bled from 
varices. 
The approach that has evolved for evaluation of sclerother-
apy failures at Emory over the last several years is a 
continuation of the work that has been done since 1971. All 
patients who are referred are evaluated with quantitative 
studies of the hepatic data base, which includes studies to 
quantitate liver function, heaptic hemodynamics, liver vol-
ume, and liver biopsy. These define the hepatic reserve, 
which dictates therapy. We believe that no single therapy is 
the best therapy for all patients. 
Two examples explain the use of this system. 
First, a 50-year-old man with posthepatic cirrhosis experi-
enced rebleeding in gastric varices after 10 sclerotherapy 
sessions. This patient had been classified in Child's class C, 
but further evaluation with the quantitative studies showed 
that he had excellent hepatic function by galactose elimina-
tion capacity and also by the results of the amino acid 
tolerance test generated after protein load. 
Liver blood flow was elevated. Portal blood flow was 
prograde. He had maintenance of liver volume. His biopsy 
showed stable cirrhosis without marked activity. 
Our assessment of the situation was that the patient had 
excellent heptic reserve. He underwent a distal splenorenal 
shunt with splenopancreatic disconnection. He has recently 
completed his I-year evaluation in our Clinical Research 
Center and is doing well. He is back at work. 
Retrograde comparison of this patient's quantitative stud-
ies and the results of the 12-year follow-up of Emory's 
controlled trial lead us to believe that this man has an 
excellent chance of having a 10-year or IS-year survival. 
The second patient was a 32-year-old woman with chronic 
active cirrhosis. She bled from gastric and duodenal varices. 
She was classified as belonging to Child's class B. Evaluation 
of her quantitative studies showed a marked deterioration in 
quantitative function and a small liver. She had reversal of 
portal flow. Our feeling was that this patient had very limited 
hepatic reserve. 
She underwent a liver transplant. She was our second 
patient. and she has just completed a I-year follow-up and is 
doing well. 
Again. we believe that no single therapy represents the best 
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treatment for all patients, and we think that the therapy for 
sclerosis failures should be based on a!lalysis of functional 
hepatocyte reserve. 
Again, the Emory group appreciates the opponunity to 
review this manuscript. We think it is a very significant 
contribution and congratulate Dr. Iwatsuki on his presenta-
tion. 
Dr. L. Rikkers (Omaha, :Keb.). I would agree with the 
two previous discussants that Dr. Iwatsuki's conclusions may 
go a bit too far. 
I agree that many nonalcoholic cirrhosis patients with 
end-stage liver disease who bleed from varices are better 
served by liver transplantation than by shunt surgery or 
sclerotherapy. In our institution, liver transplantation has 
been more responsible for the marked decline in the number 
of shunts performed than has sclerotherapy. 
However, many alcoholic cirrhosis patients in whom 
sclerotherapy fails are not candidates for liver transplanta-
tion, and we believe that shunt surgery still plays a major role 
in the management of these patients. 
If one is forced to reson to shunt surgery for whatever 
reason in a patient who is a future candidate for liver 
transplantation, which shunt would you prefer be done? 
Sedond, if you are doing a liver transplant in a patient who 
has had a previous distal splenorenal shunt, do you think that 
the shunt should be dismantled? We recently transplanted a 
liver into a patient with a distal splenorenal shunt, and a 
postoperative ponal vein thrombosis developed. Our two 
transplant surgeons, Dr. Wood and Dr. Shaw, also per-
formed a splenectomy, but the shunt remained functional and 
stole blood from the ponal vein, which then thrombosed. I 
would be interested to know how you approach this prob-
lem. 
Dr. Iwatsuki (closing). First, I would like to answer the 
questions of Dr. Wexler. The main indication for liver 
transplantation in all our patients is liver failure, not variceal 
hemorrhage. I have not said that all esophageal bleeders 
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should undergo liver transplantation. I said that we should 
try long-term sclerotherapy first. If we try enough sclerother-
apy, we can avoid shunt operations. As the control studies at 
Emory University and the University of Nebraska indicate, 
there are actually more survivors among patients with 
long-term sclerotherapy than among those with shunts. We 
are doing probably too many shunt operations for no good 
reasons. 
It is still not cenain whether the prognosis for alcoholic 
cirrhosis is worse than that for nonalcoholic cirrhosis after 
shunt operation; at least it is not clear in the literature. 
Although not included in the text, there were approximate-
ly 10 patients who went into the operating room with active 
variceal bleeding. All the variceal bleeding stopped immedi-
ately after the liver transplantation. 
Dr. Millikan, I agree with you that the measurement of 
hepatic reserve is very imponant. Child's classification was 
based on clinical observation of alcoholic cirrhosis. It is still a 
very useful classification, but it may not be applied to the 
patients who have primary biliary cirrhosis, sclerosing cho-
langitis, or biliary atresia. Their bilirubin levels are usually 
too high for Child's classification. 
Dr. Rikkers asked me what kind of shunt operation I 
would do if I had to do one. For more than 7 years in 
Pittsburgh we have done fewer than 10 shunt operations for 
bleeding varices. From the transplant point of view, I prefer 
to stay away from the hepatic hilum if I have to do a shunt 
operation. I probably prefer an H-graft mesocaval shunt. It is 
a simple operation, and the shunt can be taken down easily. 
Distal splenorenal shunt may be my second choice. This 
operation has been modified twice. More and more devascu-
larization has been added, which may create some difficulty 
during transplant hepatectomy. The distal splenorenal shunt 
should be taken down when the portal flow is not adequate. 
In many cases the ponal flow increased after removal of the 
shunt, namely, splenectomy. 
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